bma statins and transplantation
TRANSCRIPT
![Page 1: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/1.jpg)
HMG-CoA Reductase Inhibitors as Immunomodulators
Potential Use in Transplant Rejection
Liza J. Raggatt and Nicola C. PartridgeDrugs 2002; 62 (15): 2185-2191
PowerPoint presentation done by Nabil Zeidan
![Page 2: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/2.jpg)
Use of Statins after organ transplantation
• Most transplants are allografts
• Today immunosuppressive agents (e.g., cyclosporin A) can prevent acuteacute rejection, however, may induce hyperlipidimia
• Observation: Hyperlipidimia may promote chronic rejection [1]
• Statins initially given to blood lipids in transplant recipients and improve long term graft survival.
![Page 3: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/3.jpg)
• In heart transplants recipients, one study found that statins improved one year survival [2].
• However, another study found no effect on acute rejection episodes or episode severity following fluvastatin fluvastatin treatment [3].
• In one report it was observed that pravastatinpravastatin could improve chronic rejection outcome when given in combination with other immunosuppressive agents [4].
Use of Statins after organ transplantation
![Page 4: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/4.jpg)
Biological actions of Statins
• Statins lower blood cholesterol by competitively inhibiting HMG-CoA reductase, which catalyzes the rate limiting step in biosynthesis of cholesterol, and by up-regulating LDL receptors on cells.
• Reduced production of cholesterol also is accompanied by a decrease in the levels of cholesterol pathway intermediates, including isoprenoids.
• Isoprenoids are added to crucial proteins (e.g., Ras, Rho Rac) as part of post-translational events. Inhibition of isoprenoid production prevents function of these proteins.
![Page 5: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/5.jpg)
• Statins can bind Leukocyte Function-Associated Antigen-1 (LFA-1) in cholesterol and mevalonate independent way and prevent it from interacting with other receptors [24]
Biological actions of Statins
![Page 6: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/6.jpg)
Some observed immunomodulatory and anti-inflammatory effects
• Statins affect cytokine activity (in a study heart cytokine activity inhibited [11]).
• Statins have antiprolerative activity on mesangial and endothelial cells by cholesterol-independent ways [12,13]
• They lower intracellular isoprenoid intermediates [12]• They up-regulate Bone Morphogenic Protein-2 (BMP-
2) production (important for bone formation) [14]• They suppress T-cell response [18]• They lower chemokine response in PBMC [19]• They inhibit MHC-II induction [20]
![Page 7: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/7.jpg)
The class II major histocompatibility complex (MHC) and T cell activation
• Engagement of MHC-II and T-cell Receptors (TCRs) is required for helper T-cell (Th cells) differentiation and proliferation.
• This interaction is crucial to produce effector Th cells.
![Page 8: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/8.jpg)
Class II MHC and transplant rejection
• In allogeneic transplantation the tissue is attacked by the immune system of the host.
• Recognition of the MHC-II molecule as a foreign antigen (Ag), not the loaded peptide, induces the attack [25].
![Page 9: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/9.jpg)
Molecular mechanisms behind statins’ immunomodulatory effects
• Statin treatment to IFN-γ-stimulated primary macrophages and endothelial cells has been shown to lower inducible MHC-II transcription + translation [20]
![Page 10: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/10.jpg)
However, is it in a
cholesterol-dependent manner ?
![Page 11: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/11.jpg)
• Statins prevent LFA-1 & ICAM-1 binding which is crucial for T-cell activation [24]
• Synthetic statin analogues that can bind to LFA-1 but not HMG-CoA was observed to inhibit T-cell activation [24]. However, some of the inhibitory effect was suppressed by mevalonate addition.
Molecular mechanisms behind statins’ immunomodulatory effects
![Page 12: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/12.jpg)
• Vascular endothelial cells act like Antigen Presenting Cells (APCs) during the process of transplant rejection [45] and promote rejection.
• By lowering MHC-II expression on vaslcular endothelial cells and by preventing LFA-1/ICAM-1 interaction, statins may prevent rejection. [20, 24].
Molecular mechanisms behind statins’ immunomodulatory effects
![Page 13: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/13.jpg)
• The authors in this article conclude by saying that manipulation of the immune system may harmful. They gave the example of the Altered Peptide Ligands (ALPs).
• However, they also say that although statins may possess immunomodulatory properties, no convincing reports show that statins make the host more susceptible to infections at the clinically given dose [47].
• A better understanding of cholesterol synthesis in relation to HMG-CoA inhibition and LFA-1 mediated Th1 response inhibition is needed.
Molecular mechanisms behind statins’ immunomodulatory effects
![Page 14: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/14.jpg)
References• Article numbering was used1 - Isoniemi H. Hyperlipidemia after renal transplantation-facts and potential
implications. Nephrol Dial Transplant 1995; 10: 457-9
2 - Keogh A, Macdonald P, Kaan M, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529-37
3 - Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001; 60: 1990-7
4 - Katznelson S,WilkinsonAH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996; 61: 1469-74
10 - Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependentcoronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24
![Page 15: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/15.jpg)
References11 -Weis M, Pehlivanli S, Bruno M, et al. . Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38: 814-8
12 - Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117-25
13 - Massy ZA, Guijarro C, O’Donnell MP, et al. Regulation of mesangial cell proliferation by the mevalonate pathway. Contrib Nephrol 1997; 120: 191-6
14 - Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1825-6
![Page 16: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/16.jpg)
References18 -Kurakata S, Kada M, Shimada Y, et al. Effect of different inhibitors of
3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmocology 1996; 34: 51-61
19 - RomanoM, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 2000; 80: 1095-100
20 - Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. NatMed 2000; 6: 1299-402
24 - Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-92
25 - Meyer D, Thompson G. How selection shapes variation of the human major histocompatibility complex: a review. Ann Hum Genet 2001; 65: 1-26
![Page 17: Bma statins and transplantation](https://reader038.vdocument.in/reader038/viewer/2022100501/559cd2f71a28ab667f8b47a2/html5/thumbnails/17.jpg)
45 - Yun S, Rose ML, Fabre JW. The induction of major histocompatibility complex class II expression is sufficient for the direct activation of human CD4+ T cells by porcine vascular endothelial cells. Transplantation 2000; 69: 940-4
47 - Genain CP, Zamvil SS. Specific immunotherapy: one size does not fit all. Nat Med 2000; 6: 1098-100
References